iZafe Group ABFRA:M02 -5.06%48 EBITDA Margin % is -177.78% as of Mar. 2026. GuruFocus rates FRA:M02 with a GF Score™ of 48/100 and a GF Value™ of €0.04 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, iZafe Group AB ranks worse than 87.13% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. iZafe Group AB's EBITDA for the
three
months ended in Mar. 2026 was €-0.40 Mil. iZafe Group AB's Revenue for the
three
months ended in Mar. 2026 was €0.23 Mil. Therefore, iZafe Group AB's EBITDA margin for the quarter that ended in Mar. 2026 was -177.78%.
iZafe Group AB (FRA:M02) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
iZafe Group AB EBITDA Margin % Related Terms
iZafe Group AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for iZafe Group AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M02 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, iZafe Group AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iZafe Group AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iZafe Group AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where iZafe Group AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iZafe Group AB (FRA:M02) has a EBITDA Margin % of -177.78% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on iZafe Group AB and its competitors. According to the industry distribution chart, iZafe Group AB ranks #711 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 87.1%.
Is iZafe Group AB's EBITDA Margin % too high?
iZafe Group AB's current EBITDA Margin % is -177.78%. Based on the distribution chart, iZafe Group AB ranks #711 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, iZafe Group AB has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iZafe Group AB's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, iZafe Group AB ranks #711 out of 816 companies for EBITDA Margin %. This places iZafe Group AB in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on iZafe Group AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iZafe Group AB's current EBITDA Margin % is -177.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iZafe Group AB stock overvalued right now?
Based on GuruFocus' analysis, iZafe Group AB (FRA:M02) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.04, compared to a current price of €0.03 — trading 15.5% below its estimated fair value. The current EBITDA Margin % is -177.78%. iZafe Group AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For iZafe Group AB (FRA:M02), the current EBITDA Margin % is -177.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iZafe Group AB (FRA:M02) Overvalued in 2026?
Based on GuruFocus' analysis, iZafe Group AB stock appears to be undervalued.
The current stock price of €0.03 is trading 15.5% below its estimated GF Value™ of €0.04.
GuruFocus considers iZafe Group AB to be Modestly Undervalued.
Key valuation signals for FRA:M02:
EBITDA Margin %: -177.78%
GF Value™: €0.04 vs. price of €0.03 (15.5% below fair value)
No single metric tells the full story. See the FRA:M02 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iZafe Group AB is a Developer of a digital medication dispensing system designed to enhance patient safety and reduce medication errors in home healthcare. The company offers a smart medication robot with automated dispensing and remote monitoring, enabling public and private healthcare providers in Sweden, the Nordics, and international markets, improved treatment adherence and reduced caregiver workload.
48GF Score
Get the complete analysis for FRA:M02
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M02 has been successfully added to your 
